Incyte Will Tap Agenus Platform To Move Into Checkpoint Modulator Space
This article was originally published in The Pink Sheet Daily
Executive Summary
Five-year collaboration against four targets could provide combination potential with Incyte’s small-molecule lead candidate, an oral indoleamine dioxygenase-1 inhibitor. The transaction marks Agenus’ second deal around its Retrocyte Display platform since it acquired the technology one year ago.